Cell Therapy Tools for Cartilage Repair From Osteoarthritic Knee Joint of Elderly
A break through feat of growing pluripotency expressing cells from osteoarthritis (OA) affected cartilage tissue of knee joints of elderly has been reported by orthopedicians and cell culture experts led by Dr Shojiro Katoh, President, Edogawa Hospital. OA affects, knee joints of millions globally and those with severe disease, undergo Total Knee Arthroplasty (TKA), in which damaged cartilage is replaced with artificial knee prosthesis. Dr Katoh, during TKA surgery, took portions of the damaged tissue, which otherwise is discarded, isolated chondrocyte cells in tissue engineering lab, and could culture them as fully reorganized healthy cartilage tissue, expressing biomarkers relevant to pluripotency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200617005880/en/
"Pluripotency expressing cells grown from osteoarthritis affected knee joint, open doors to a spectrum of novel solutions to address cartilage damage," says Dr. Shojiro Katoh, President, Edogawa Hospital, Tokyo, Japan. (Photo: Business Wire)
Cartilage of the knee joint acts as a cushion between bones of the thigh and leg and absorbs the body weight. When cartilage is damaged due to sports injury, trauma or wear and tear, it causes joint pain and disability. In early stage of the disease, Autologous Chondrocyte Implantation (ACI) or Matrix Assisted Chondrocyte Implantation (MACI) are practiced. Such cell therapies use patient’s own cartilage cells, harvested from healthy, non-weight bearing area, grown in lab, and transplanted to replace the damaged tissue, to restore functionality.
"This could probably be the world’s first report of Osteoarthritis tissue, yielding cells expressing pluripotency markers," said Dr. Katoh, citing their publication in Regenerative Therapy Journal (https://www.sciencedirect.com/science/article/pii/S2352320420300274), also presented in the 19th Japanese society for regenerative medicine meeting. "Our technique may help utilize OA affected cartilage, discarded as biomedical waste, as a source of tools of cell therapies viz., cells, cell secreted growth factors, and exosomes to repair cartilage defects in regenerative medicine," he added.
Edogawa hospital, located in eastern Tokyo, has many senior citizens. "Contrary to the age-old belief that Wisdom is the strength of elders, this research finding has made me humble, to learn about nature’s hidden strength in their physical intricacies too, fueling our enthusiasm," said Dr Katoh adding a philosophical humility to his accomplishment. His Edogawa Evolutionary Lab of Science (EELS), having confirmed hyaline phenotype is now evaluating miRNA-140 and Hyaluronan expression of chondrocytes.
This technology has a potential to solve cartilage damage of approximately 12 million people annually worldwide, according to JBM Inc, and GN Corporation, co-applicants to a patent and research partners to EELS.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005880/en/
Contact information
Samuel JK Abraham
GN Corporation
info@gncorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF to Release Third Quarter 2025 Results on Nov. 4, 202514.10.2025 23:15:00 EEST | Press release
IFF (NYSE:IFF) today announced that it will release its third quarter 2025 earnings results following the market close on Tuesday, Nov. 4, 2025. The management team will host a live webcast on Wednesday, Nov. 5, 2025, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20251014533502/en/
TRU Simulation and US Aviation Academy sign purchase agreement for five Cessna Skyhawk Veris Virtual Reality Simulators, signifying first fleet order and fixed-wing market debut14.10.2025 21:39:00 EEST | Press release
During the National Business Aviation Association – Business Aviation Convention & Exhibition (NBAA-BACE), TRU Simulation + Training Inc., a Textron Inc.(NYSE:TXT) company, and an affiliate of Textron Aviation Inc., announced an agreement with the US Aviation Academy for its purchase of five of TRU Simulation’s Cessna Skyhawk Veris Virtual Reality (VR) Simulators. This landmark agreement introduces the Veris to the fixed-wing training market and is TRU Simulation’s first fleet order for VR training devices. The US Aviation Academy has the option for a future purchase of ten additional units as part of the agreement, underscoring a shared commitment to advancing pilot training through cutting-edge VR simulation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013144401/en/ TRU Simulation and US Aviation Academy sign purchase agreement for five Cessna Skyhawk Veris Virtual Reality Simulators, signifying first fleet order and
Introducing Lasso: A New Food Tech Company Redefining Consumer Packaged Foods14.10.2025 20:34:00 EEST | Press release
Lasso today announced its official launch and the introduction of its proprietary technology, Lasso SpinTech. This breakthrough system upends the outdated standards of ultra-processed foods using physics to weave together protein and fiber to make previously unattainable new consumer products. With a new $6.5M raise, Lasso is bringing its technology to the world by launching its own brands and licensing to global partners to create a new generation of healthier foods. Guided by CEO Mike Messersmith, the Lasso team spent the past year deploying its commercial-scale technology to create innovative clean-label products including protein-packed snacks and pet food—expanding beyond its first plant-based meat application under the Tender Food brand. Lasso’s latest $6.5M in capital, led by Rhapsody Venture Partners with participation from Safar Partners, Claridge Venture Partners, and others, will enable the company to commercialize its transformative technology across new high growth food ca
Rimini Street to Report Third Quarter 2025 Financial Results on October 30, 202514.10.2025 19:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on October 30, 2025. The company will host a conference call and webcast on that date to discuss the third quarter and the 2025 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014139026/en/ A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a proven,
Esri’s ArcGIS Maritime to Support Next-Generation S-100 Production Capabilities for Advanced Nautical Charting14.10.2025 19:00:00 EEST | Press release
Esri, the global leader in geographic information system (GIS) technology, announced new capabilities in ArcGIS Maritime to support production of S-100 compliant nautical charts, marking a major milestone in the evolution of hydrographic data management. Maritime organizations will also be able to generate S-57 charts alongside S-101 charts, which will enable them to more seamlessly leverage GIS. Crucial for supporting the latest spatial data and technologies, the shift to S-100 ready charting will enhance maritime navigation, safety, and situational awareness. The new S-100 series of standards developed by the International Hydrographic Organization (IHO) introduces a modern, extensible framework for electronic navigational charts, bathymetric data, and other marine information products. “The core mission of maritime authorities like hydrographic offices is supporting safe navigation, but they are increasingly being called upon to support broader priorities like the blue economy and e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom